Bravias Capital Group’s AbbVie ABBV Stock Holding History

Bravias Capital Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-969	Closed	-$224K	–	109
2025 Q3	$224K	Buy	+969	New	+$197K	0.15%	96

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bravias Capital Group's ABBV Position: Q4 2025 in Review

Bravias Capital Group sold out of AbbVie (ABBV) in Q4 2025, closing a stake of 969 shares — an estimated $224K sold.

Bravias Capital Group first reported a position in ABBV in Q3 2025 and held it in 1 quarter. The position peaked at $224K in Q3 2025. 4,148 funds tracked by Wall St. Rank hold ABBV as of Q4 2025.

Bravias Capital Group reported no remaining AbbVie position as of Q4 2025 after selling out during the quarter.
Bravias Capital Group sold 969 AbbVie shares in Q4 2025, an estimated $224K.
Bravias Capital Group first reported a position in AbbVie in Q3 2025 and held it in 1 quarter.
Bravias Capital Group's AbbVie position peaked at $224K in Q3 2025.
4,148 funds tracked by Wall St. Rank held AbbVie as of Q4 2025.

Based on Bravias Capital Group's 13F filing for Q4 2025, filed 29 Jan 2026.